CSIMarket
 


Glaukos Corp  (GKOS)
Other Ticker:  
 
 

GKOS's Capital Expenditures Growth by Quarter and Year

Glaukos's Capital Expenditures results by quarter and year




GKOS Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 4.21 8.22 9.33 1.28
III Quarter September 3.36 6.04 9.92 2.73
II Quarter June 5.77 9.40 11.36 0.78
I Quarter March 6.91 6.60 17.18 1.19
FY   20.25 30.26 47.79 5.98



GKOS Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Glaukos Corp reported drop in Capital Expenditures in the fourth quarter 2023 by -48.73% to $ 4.21 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Glaukos Corp's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures jump of 91.8%.

Looking into fourth quarter 2023 results within Medical Equipment & Supplies industry 22 other companies have achieved higher Capital Expenditures growth. While Glaukos Corp' s Capital Expenditures meltdown of -48.73% ranks overall at the positon no. 556 in the fourth quarter 2023.




GKOS Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -48.73 % -11.9 % 628.91 % 26.73 %
III Quarter September -44.37 % -39.11 % 263.37 % 45.99 %
II Quarter June -38.62 % -17.25 % 1356.41 % 20 %
I Quarter March 4.7 % -61.58 % 1343.7 % -84.3 %
FY   -33.07 % -36.68 % 699.16 % -46.17 %

Financial Statements
Glaukos's fourth quarter 2023 Capital Expenditures $ 4.21 millions GKOS's Income Statement
Glaukos's fourth quarter 2022 Capital Expenditures $ 8.22 millions Quarterly GKOS's Income Statement
New: More GKOS's historic Capital Expenditures Growth >>


GKOS Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 25.42 % 36.09 % -5.95 % -53.11 %
III Quarter September -41.77 % -35.74 % -12.68 % 250 %
II Quarter June -16.5 % 42.42 % -33.88 % -34.45 %
I Quarter March -15.94 % -29.26 % 1242.19 % 17.82 %
FY (Year on Year)   -33.07 % -36.68 % 699.16 % -46.17 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #61
Overall #556

Capital Expenditures Y/Y Growth Statistics
High Average Low
698.55 % 91.8 % -191.06 %
(Dec 31 2021)   (Mar 31 2017)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #61
Overall #556
Capital Expenditures Y/Y Growth Statistics
High Average Low
698.55 % 91.8 % -191.06 %
(Dec 31 2021)   (Mar 31 2017)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Glaukos's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
6222.67 % 254.25 % -91.41 %
(Mar 31 2016)  


GKOS's IV. Quarter Q/Q Capital Expenditures Comment
Glaukos Corp achieved in the IV. Quarter 2023 below company average Capital Expenditures jump of 25.42% quarter on quarter, to $ 4.21 millions.

Within Medical Equipment & Supplies industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Glaukos's Capital Expenditures growth quarter on quarter, overall rank is 352.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #20
Healthcare Sector #45
Overall #352
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #20
Healthcare Sector #45
Overall #352
Capital Expenditures Q/Q Growth Statistics
High Average Low
6222.67 % 254.25 % -91.41 %
(Mar 31 2016)  


GKOS's IV. Quarter Q/Q Capital Expenditures Comment
Glaukos Corp achieved in the IV. Quarter 2023 below company average Capital Expenditures jump of 25.42% quarter on quarter, to $ 4.21 millions.

Within Medical Equipment & Supplies industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Glaukos's Capital Expenditures growth quarter on quarter, overall rank is 352.


Glaukos's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 20.25 $ 24.26 $ 26.93 $ 30.57 $ 30.27
Y / Y Capital Expenditures Growth (TTM) -33.1 % -22.68 % -23.59 % -17.84 % -36.66 %
Year on Year Capital Expenditures Growth Overall Ranking # 786 # 1801 # 355 # 398 # 35
Seqeuential Capital Expenditures Change (TTM) -16.52 % -9.95 % -11.89 % 1 % -3.53 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 556 # 1634 # 1566 # 1571 # 896




Cumulative Capital Expenditures growth Comment
Glaukos's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -33.1% year on year, at Dec 31 2023 compare to the -22.68% decrease at Sep 30 2023. If the Glaukos's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $20 millions.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 786, from total ranking in previous quarter at 1801.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
698.55 %
91.8 %
-191.06 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 23
Healthcare Sector # 85
Overall # 786

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
698.55 %
91.8 %
-191.06 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 61
S&P 500 # 556
Cumulative Capital Expenditures growth Comment
Glaukos's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -33.1% year on year, at Dec 31 2023 compare to the -22.68% decrease at Sep 30 2023. If the Glaukos's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $20 millions.

In the Healthcare sector 84 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 786, from total ranking in previous quarter at 1801.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
698.55 %
91.8 %
-191.06 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 23
Healthcare Sector # 85
Overall # 786

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
698.55 %
91.8 %
-191.06 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 61
S&P 500 # 556




Other Capital Expenditures Growth
Medical Equipment & Supplies Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
GKOS's Capital Expenditures Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for GKOS's Competitors
Capital Expenditures Growth for Glaukos's Suppliers
Capital Expenditures Growth for GKOS's Customers

You may also want to know
GKOS's Annual Growth Rates GKOS's Profitability Ratios GKOS's Asset Turnover Ratio GKOS's Dividend Growth
GKOS's Roe GKOS's Valuation Ratios GKOS's Financial Strength Ratios GKOS's Dividend Payout Ratio
GKOS's Roa GKOS's Inventory Turnover Ratio GKOS's Growth Rates GKOS's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com